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Abstract
The emergence of XDR TB coupled with the high prevalence of HIV/AIDS has intensified the need to identify new 
treatment strategies and accelerate research into antibiotics against XDR TB before the world is faced with a global 
public health crisis. This article gives a short overview on the important health implications of XDR-TB in South 
Africa. 
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Introduction
The developing world awaits a catas-
trophe as tuberculosis (TB) places a 
burden on the public health system and 
is increasingly becoming the leading 
infectious cause of escalating morbid-
ity globally. Years of extensive research 
into effective therapeutic strategies to 
combat this disease, have not succeed-
ed in eradicating the causative agent 
- Mycobacterium tuberculosis. Poor drug 
compliance, poverty and HIV co-infec-
tion have contributed to the emergence 
of multidrug resistant strains of TB (MDR 
TB). Figure 1 shows the global burden 
of MDR TB with the highest prevalence 
in south-east Asia. While combinations 
of first and second line antibiotics have 
been effective in treating MDR TB, the 
world was alarmed when a new strain of 
extensively drug resistant TB (XDR TB) 
emerged in the early nineties. In 2006, 
South Africa became one the countries 
hardest hit by XDR TB when 52 out of 
53 patients infected with this strain of TB 
died  within a short period of time (98% 
case fatality rate). The emergence of 
XDR TB coupled with the high preva-
lence of HIV/AIDS has intensified the 
need to identify new treatment strate-
gies and accelerate research into antibi-
otics against XDR TB before the world is 
faced with a global public health crisis.
Current management of TB
Globally, TB is a world wide threat, caus-
ing three million deaths annually, with 8 
million new active cases per year.1  Re-
ports from the World Health Organiza-
tion (WHO), estimates that an alarming 
2.4 million people were infected with TB 
Figure 1: MDR TB by Geographical Regions
Source: National Department of Health, South Africa. The Emerging Global Threat of XDR-Tb. TB Workshop 17-18 Oct, 2006 
www.doh.gov.za/docs/thexdr-tb-f.html (accessed 22 November 2006)
in 2001, making TB the most infectious 
agent in the world.2 Currently the first 
line anti-TB drugs used are isoniazid, 
rifampin ethambutol, and pyrazinamide. 
These drugs are reasonably effective in 
treating individuals suffering from TB 
but are ineffective in totally eliminating 
the bacilli.3 A setback of this regimen is 
that the course of treatment which lasts 
a minimum of six months is perceived to 
be lengthy and involves 2 to 4 drugs, 
resulting in poor compliance.4 Poor 
compliance with the prescribed drug 
regimen coupled with their improper 
use, gives rise to multidrug resistant TB 
(MDR TB). 
Multidrug Resistant Tuberculosis 
(MDR TB) is defined as an in vitro re-
sistance of mycobacterium bacillus to 
at least rifampin and isoniazid.5 The 
development of drug resistance and 
subsequent MDR TB is caused by 
chromosomal mutations in the different 
genes of the bacteria. MDR TB devel-
ops when a sequence of these muta-
tions allows bacteria to become resis-
tant to one drug or a group of drugs 
e.g. (rifamycins) at a time.6 Currently 
MDR TB strains resistant to up to nine 
different agents have been reported.7 
Usually drug susceptible TB can be 
cured within 6 months but MDR TB 
requires intense chemotherapy for up 
to 2 years and this is very detrimental to 
a patient’s health, due to high levels of 
drug toxicity.8 
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Cost of TB treatment
The cost of anti-TB medication for a 
patient on the six-month regimen is 
approximately three hundred and sev-
enty-seven rand (R377), while for MDR 
TB, it is about thirty-one thousand rand 
(R31000) for the same period of time. 
The drug cost for XDR TB is not yet 
known but it is expected to be more ex-
pensive than that for MDR TB . The only 
drugs available to treat XDR TB in South 
Africa are ethionamide and cycloserine, 
which are currently being administered 
at King George V Hospital, Durban. 
In countries where the rate of primary 
multidrug-resistant TB is low, standard 
treatment regimens include rifampin 
and isoniazid throughout the duration 
of therapy in addition to pyrazinamide 
(with or without ethambutol) for the first 2 
months.9 MDR TB treatment requires the 
use of second-line drugs, such as qui-
nolones (ciprofloxacin, ofloxacin, spar-
floxacin) that are less effective, more 
toxic, and costlier than first-line iso-
niazid- and rifampin-based regimens.10 
Aminoglycosides such as capremycin, 
viomycin, kanamycin and amikacin 
are also used in drug resistant situa-
tions.11 It is worrying that no new first 
line antibiotics have been identified for 
the treatment of TB in the last 20 years.6 
Furthermore poor patient co-operation, 
poor quality of medicine as well as logis-
tical problems have contributed to the 
increase in MDR TB cases.6 MDR TB is 
largely a consequence of human activity 
as it did not exist before the introduction 
of chemotherapeutic drugs.12 
Epidemiology of XDR TB
Extensively drug resistant tuberculosis 
(XDR TB) was originally defined as the 
presence of Mycobacterium tuberculo-
sis isolates resistant to at least isoniazid 
and rifampin (MDR TB), plus additional 
resistance to at least three of the six 
classes of second-line drugs used to 
treat persons with MDR TB.13 These 
forms of tuberculosis are both more 
difficult and expensive to treat. XDR TB 
is of particular concern among persons 
with HIV infection or other conditions 
that weaken the host’s immunity. These 
persons are more likely to develop TB 
disease once they become infected with 
Mycobacterium tuberculosis, have been 
associated with a higher risk of death 
and the greatest concern is that XDR TB 
leaves some patients virtually untreat-
able with currently available drugs.13
In 2000, the Centers for Disease Con-
trol and Prevention (CDC), United States 
reported that 64% of patients affected 
by X-DR-TB died.12 Between 2000 and 
2004, the CDC and WHO surveyed an 
international network of TB laboratories 
to assess the number of cases of MDR 
and XDR TB.  Of the 17,690 TB isolates, 
20% were MDR and 2% were XDR.10 
Countries with records of XDR TB in-
clude United States (1993-2004), Latvia 
(2000-2002) and South Korea (2004) 
where 4%, 19% and 15% of their MDR 
TB cases, were XDR TB respectively.10 
In addition, a study conducted by the 
National Research Institute of TB and 
Lung diseases in Tehran, Iran between 
2003 and 2005, showed that 10.9% of 
MDR TB strains tested were resistant to 
all eight second line drugs and  these 
strains were identified as belonging to 
the MTB super family Harlem 1 and East 
African Indian.14 The recent situation at 
Tugela Ferry in Kwa-Zulu Natal, South 
Africa is considered to be the tip of the 
ice berg in which 52 of the 53 patients 
co-infected with HIV/AIDS died. 
Current global strategies for XDR TB
In an effort to curb the spread of XDR 
TB, the South African Medical Research 
Council, WHO and the US Center for Dis-
ease Control and Prevention in TB pro-
pose the following seven point plan: 15
a.  Rapid surveys to assess the current 
prevalence of  XDR TB globally 
b.  Enhanced local laboratory capacity 
to carry out culture and drug resis-
tance testing
c.  Increased training of public health 
staff to identify, investigate and treat 
XDR TB outbreaks
d.  Implementation of infection control 
precautions
e.  Increased research support for drugs 
to treat XDR TB
f.  Development of rapid diagnostic 
tests for TB 
g. Access to antiretroviral drugs 
For the family practitioner, there are 
a number of important issues to con-
sider in implementing these strategies 
namely: 
a.  the need for forced hospitalization 
and compulsory treatment of these 
patients to reduce community expo-
sure
b.  Maintenance of confidentiality with 
the diagnosis 
c.  Possible stigmatization of these pa-
tients by other patients and the com-
munity 
Other issues include the difficulty of 
making a diagnosis in such patients 
without running the risk of exposure to 
the infection by health care workers, ac-
cessibility to the drugs needed for their 
treatment and availability of isolation 
facilities e.g. XDR TB isolation wards or 
hospitals. The diagnosis of XDR TB will 
most probably be made by elimination 
after a patient on  MDR TB treatment 
fails to respond to both first and second 
line regimens. The dilemma lies with 
the non-specific symptoms or signs for 
these patients beyond the non-response 
to treatment and laboratory isolation of 
extensively resistant strains of TB.
Conclusions
According to the South African National 
Health Act 61 of 2003, section 20, sub-
section 3 (b), “subject to any applicable 
law, every health establishment must im-
plement measures to minimize disease 
transmission”.16 This implies that XDR 
TB should be a notifiable disease and 
the attending doctor has a legal obliga-
tion to supply all relevant information on 
the patient to the provincial health de-
partment who in turn has an obligation 
to transfer sufficient information to the 
national Department of Health (NDOH), 
in order to protect the larger population 
at risk. The emergence of XDR TB poses 
a threat in becoming a future epidemic 
that will complicate the HIV pandemic 
and plague mankind. It highlights the 
need for more aggressive focus on new 
anti-TB regimens, better diagnostic tests 
and stricter policy with regard to control 
and detection strategies. The national 
and provincial departments of health 
must as a matter of urgency identify well 
designed isolation units in all provinces 
to cope with the unknown number of 
possible or probable XDR TB patients 
that are already in the community. 
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